Global Broker Regulation Inquiry App

About WikiFX

Broker Search

English

简体中文

繁體中文

English

Pусский

日本語

ภาษาไทย

Tiếng Việt

Bahasa Indonesia

Español

हिन्दी

Filippiiniläinen

Français

Deutsch

Português

Türkçe

한국어

العربية

اردو

Download

WikiFX Express

Indonesias palm oil export ban leaves global buyers with no plan B

Roche Q1 sales up 10%, confirms 2022 outlook

WikiFX

| 2022-04-25

Abstract：(Reuters) – Swiss drugmaker Roches first quarter sales rose 10%, driven by drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia, and on strong U.S. demand for rapid COVID-19 antigen tests.

div classBodysc17zpet90 cdBBJodivpReuters – Swiss drugmaker Roches first quarter sales rose 10, driven by drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia, and on strong U.S. demand for rapid COVID19 antigen tests.

Quarterly sales rose to 16.44 billion Swiss francs 17.17 billion, up from 14.93 billion Swiss francs in the yearearlier period, the company said on Monday. That was slightly above a market consensus of about 16 billion francs.pdivdivdiv classBodysc17zpet90 cdBBJodiv

Roche also confirmed its guidance for 2022.

1 0.9577 Swiss francs

Reporting by Ludwig Burger Editing by Miranda Murray

divdivdiv classBodysc17zpet90 cdBBJodivdivdiv

Disclaimer:

The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.